. "87190" . "L\u00E1nsk\u00E1, V\u011Bra" . "N" . "M\u00E9n\u011B \u010Dast\u00E9 indikace k ortotopick\u00E9 transplantaci jater" . . "M\u00E9n\u011B \u010Dast\u00E9 indikace k ortotopick\u00E9 transplantaci jater"@cs . "Souhrn: K 13. 8. 2013 bylo v Institutu klinick\u00E9 a experiment\u00E1ln\u00ED medic\u00EDny (IKEM) v Praze provedeno celkem 1 000 transplantac\u00ED jater, z toho v 84 (8,4 %) p\u0159\u00EDpadech pro m\u00E9n\u011B \u010Dast\u00E9 diagn\u00F3zy. Indika\u010Dn\u00ED proces je v t\u011Bchto p\u0159\u00EDpadech n\u00E1ro\u010Dn\u011Bj\u0161\u00ED ne\u017E u b\u011B\u017En\u00FDch diagn\u00F3z, proto\u017Ee chyb\u00ED dostate\u010Dn\u00E1 zku\u0161enost a v\u00FDsledky jsou hodnoceny na mal\u00FDch souborech nemocn\u00FDch. Metody: Retrospektivn\u00ED zhodnocen\u00ED souboru nemocn\u00FDch s m\u00E9n\u011B \u010Dast\u00FDmi diagn\u00F3zami, kte\u0159\u00ED podstoupili v IKEM transplantaci jater. U vybran\u00FDch diagn\u00F3z jsme hodnotili kumulativn\u00ED p\u0159e\u017E\u00EDv\u00E1n\u00ED pacient\u016F a \u0161t\u011Bp\u016F. V\u00FDsledky: Nej\u010Dast\u011Bji byly zastoupeny polycystick\u00E1 nemoc jater, Budd-Chiariho syndrom a epiteloidn\u00ED hemangioendoteliom. Jednolet\u00E9 kumulativn\u00ED p\u0159e\u017E\u00EDv\u00E1n\u00ED pacient\u016F bylo 87 %, 82 % a 100 %, p\u011Btilet\u00E9 87 %, 72 % a 100 %. Ve skupin\u011B \u0161esti jedinc\u016F transplantovan\u00FDch pro metast\u00E1zy neuroendokrinn\u00EDch tumor\u016F v j\u00E1trech zem\u0159eli dva nemocn\u00ED. Z\u00E1v\u011Br: Ortotopick\u00E1 transplantace jater p\u0159in\u00E1\u0161\u00ED v indikovan\u00FDch p\u0159\u00EDpadech dobr\u00E9 v\u00FDsledky i ve skupin\u011B m\u00E9n\u011B \u010Dast\u00FDch diagn\u00F3z. Nemocn\u00ED s metast\u00E1zami neuroendokrinn\u00EDch tumor\u016F v j\u00E1trech p\u0159edstavuj\u00ED velmi hrani\u010Dn\u00ED indikaci. Ortotopick\u00E1 transplantace jater m\u016F\u017Ee b\u00FDt dobr\u00FDm \u0159e\u0161en\u00EDm i pro n\u011Bkter\u00E1 vz\u00E1cn\u00E1 onemocn\u011Bn\u00ED. P\u0159edpokladem \u00FAsp\u011Bchu je spr\u00E1vn\u00E1 p\u0159edtransplanta\u010Dn\u00ED rozvaha a pe\u010Dliv\u00E9 vy\u0161et\u0159en\u00ED. V\u017Edy je nutno zv\u00E1\u017Eit i mo\u017Enost konzervativn\u00ED l\u00E9\u010Dby." . . "http://www.csgh.info/dwnld/gh_2013_5_421_425.pdf" . "Trune\u010Dka, Pavel" . "CZ - \u010Cesk\u00E1 republika" . . "8"^^ . "RIV/00023001:_____/13:00058700" . . "\u0160pi\u010D\u00E1k, Julius" . "M\u00E9n\u011B \u010Dast\u00E9 indikace k ortotopick\u00E9 transplantaci jater" . "RIV/00023001:_____/13:00058700!RIV14-MZ0-00023001" . . "Gottfriedov\u00E1, Halima" . . . "liver transplantation, uncommon indications, patient and graft survival"@en . . "5" . "Summary: As of 13th August 2013, 1,000 liver transplants have been carried out at the Institute for Clinical and Experimental Medicine (IKEM) in Prague of which in 84 (8.4%) cases for an uncommon diagnosis. Indicating the process in these cases is more difficult than in conventional diagnoses, because there is insufficient experience and the results are evaluated on small samples of patients. Methods: A retrospective review of a group of patients with less frequent diagnoses who underwent orthotopic liver transplantation in IKEM. For selected diagnoses, we assessed the cumulative survival of patients and grafts. Results: The most frequent diagnoses were polycystic liver disease, Budd-Chiari syndrome and epithelioid hemangioendothelioma. Annual cumulative survival reached 87%, 82%, 100%; five-year survival was 87%, 72% and 100%. In the group of six subjects transplanted for metastatic neuroendocrine tumours in the liver two patients died. Conclusion: In the indicated cases, orthotopic liver transplantation brings excellent results in the group of uncommon diagnoses. Patients with metastases of neuroendocrine tumours in the liver represent a borderline indication. Orthotopic liver transplantation can be a good solution for some rare conditions. To succeed it is essential to carry out a careful pre-transplantation evaluation and examination. We have to always consider the possibility of a conservative treatment."@en . . "Uncommon indications for orthotopic liver transplantation"@en . . . "5"^^ . "Uncommon indications for orthotopic liver transplantation"@en . . . . . "67" . "5"^^ . "M\u00E9n\u011B \u010Dast\u00E9 indikace k ortotopick\u00E9 transplantaci jater"@cs . "Jane\u010Dkov\u00E1, Lucie" . "Gastroenterologie a hepatologie" . "Souhrn: K 13. 8. 2013 bylo v Institutu klinick\u00E9 a experiment\u00E1ln\u00ED medic\u00EDny (IKEM) v Praze provedeno celkem 1 000 transplantac\u00ED jater, z toho v 84 (8,4 %) p\u0159\u00EDpadech pro m\u00E9n\u011B \u010Dast\u00E9 diagn\u00F3zy. Indika\u010Dn\u00ED proces je v t\u011Bchto p\u0159\u00EDpadech n\u00E1ro\u010Dn\u011Bj\u0161\u00ED ne\u017E u b\u011B\u017En\u00FDch diagn\u00F3z, proto\u017Ee chyb\u00ED dostate\u010Dn\u00E1 zku\u0161enost a v\u00FDsledky jsou hodnoceny na mal\u00FDch souborech nemocn\u00FDch. Metody: Retrospektivn\u00ED zhodnocen\u00ED souboru nemocn\u00FDch s m\u00E9n\u011B \u010Dast\u00FDmi diagn\u00F3zami, kte\u0159\u00ED podstoupili v IKEM transplantaci jater. U vybran\u00FDch diagn\u00F3z jsme hodnotili kumulativn\u00ED p\u0159e\u017E\u00EDv\u00E1n\u00ED pacient\u016F a \u0161t\u011Bp\u016F. V\u00FDsledky: Nej\u010Dast\u011Bji byly zastoupeny polycystick\u00E1 nemoc jater, Budd-Chiariho syndrom a epiteloidn\u00ED hemangioendoteliom. Jednolet\u00E9 kumulativn\u00ED p\u0159e\u017E\u00EDv\u00E1n\u00ED pacient\u016F bylo 87 %, 82 % a 100 %, p\u011Btilet\u00E9 87 %, 72 % a 100 %. Ve skupin\u011B \u0161esti jedinc\u016F transplantovan\u00FDch pro metast\u00E1zy neuroendokrinn\u00EDch tumor\u016F v j\u00E1trech zem\u0159eli dva nemocn\u00ED. Z\u00E1v\u011Br: Ortotopick\u00E1 transplantace jater p\u0159in\u00E1\u0161\u00ED v indikovan\u00FDch p\u0159\u00EDpadech dobr\u00E9 v\u00FDsledky i ve skupin\u011B m\u00E9n\u011B \u010Dast\u00FDch diagn\u00F3z. Nemocn\u00ED s metast\u00E1zami neuroendokrinn\u00EDch tumor\u016F v j\u00E1trech p\u0159edstavuj\u00ED velmi hrani\u010Dn\u00ED indikaci. Ortotopick\u00E1 transplantace jater m\u016F\u017Ee b\u00FDt dobr\u00FDm \u0159e\u0161en\u00EDm i pro n\u011Bkter\u00E1 vz\u00E1cn\u00E1 onemocn\u011Bn\u00ED. P\u0159edpokladem \u00FAsp\u011Bchu je spr\u00E1vn\u00E1 p\u0159edtransplanta\u010Dn\u00ED rozvaha a pe\u010Dliv\u00E9 vy\u0161et\u0159en\u00ED. V\u017Edy je nutno zv\u00E1\u017Eit i mo\u017Enost konzervativn\u00ED l\u00E9\u010Dby."@cs . . "[A1BB51B9AB69]" . . "1804-7874" . .